Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|October 17, 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionalsCatherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, et al.
Ophthalmology and Therapy|July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Haematologica|April 1, 2021
European Myeloma Network perspective on CAR T-Cell therapies for multiple myelomaBenedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Ophthalmology and Therapy|September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Leukemia & Lymphoma|June 1, 2023
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experienceGeorge Nesr, Raakhee Shah, Charalampia Kyriakou, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2020
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosisOliver C Cohen, Maximillian H Brodermann, Iona J Blakeney, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2024
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With TalquetamabAjai Chari, Amrita Krishnan, Leo Rasche, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Pageof 9